Abivax S.A. ABVX 深 沪
交易中 09-10 11:03:35 美东时间
88.00
-1.250
-1.40%
华盛通- 最 高90.00
- 今 开90.00
- 成交量 14.07万股
- 最 低 87.99
- 昨 收 89.25
- 总市值 64.75亿
- 52周最高 92.91
- 市盈率 静 --
- 换手率 0.19%
- 52周最低 4.77
- 委 比 -33.33%
- 总股本 7357.47万
- 历史最高 92.91
- 量 比 0.48
- 振 幅 2.25%
- 历史最低 4.77
- 每 手 1
- 风险率 22.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
今天 18:01
Abivax SA Reports Financial Results and Strategic Advances
Abivax SA Sponsored ADR ( ($ABVX) ) has released its Q2 earnings. Here is a bre...
今天 11:56
BTIG Reiterates Buy on Abivax, Maintains $112 Price Target
BTIG analyst Julian Harrison reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $112 price target.
09-09 19:15
Abivax jumps amid takeover speculation
Abivax (NASDAQ:ABVX) shares rose 6.9% in Paris amid takeover speculation. Abivax ADRs gained 6%. There's speculation that Abivax (NASDAQ:ABVX) has attracted takeover interest, according to traders, wh...
09-05 23:43
Abivax’s 580% surge hands biotech hedge funds a rare 2025 win
Hedge funds specializing in biotech finally caught a break this summer, courtesy of a little-watched French drug developer, The Wall Street Journal reported on Saturday. Paris-based Abivax (NASDAQ:ABV...
08-31 20:30
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease
Abivax SA (($GB:0RA9)) announced an update on their ongoing clinical study. Abi...
08-29 00:33
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
Earnings Outlook For Abivax
Abivax (NASDAQ:ABVX) is set to give its latest quarterly earnings report on Mon...
08-08 23:01
美股周涨跌榜 | 本周飙升568%！Abivax S.A.新药III期研究成功；CRO股Medpace周涨超43%
本周飙升568%！生物技术公司Abivax S.A.溃疡性结肠炎口服药物III期研究成功；CRO股Medpace周涨超43%，Q2营收和EBITDA均超预期>>
07-26 10:23
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax, a clinical-stage biotech company developing treatments for chronic inflammatory diseases, has announced that underwriters for its offering of 10,156,000 ADSs have fully exercised their option to purchase an additional 1,523,400 ADSs. This brings the total ADSs issued to 11,679,400 and gross proceeds to $747.5 million (€637.5 million). The additional ADSs are priced at $64.00 each, reflecting a 21% premium over the average price of ordinar...
07-25 06:00
